Having demonstrated that the AP/T score was associated with efficacy in the preclinical murine models, the usefulness of the AP/T score in predicting clinical efficacy was also tested by deriving it from gene expression data (mean Z of AP/T genes) obtained from tumor tissue from patients in the clinical phase 3 OAK trial in which atezolizumab improved OS regardless of PD-L1 expression (“Supplemental Figure”). This evidence concerns the gene CD274 and neoplasm.